Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.AADI · Entity 6074 | Director | June 12, 2024 | June 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2034-06-12 | Direct | 45,832 |
Reported balance
After 2024-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 45,832 · Balance 45,832 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2024 Filed Jun 14, 2024 20:03 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 45,832 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-24-016862 · form4-06142024_080653.xml · derivative · entry 1 Hehenberger Karin M. · CIK 0001548029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,832 Underlying: Common Stock · 45,832 shares Expires 2034-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2024. Read SEC document |
| June 15, 2023 Filed Jun 21, 2023 00:18 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 28,255 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001209191-23-038661 · doc4.xml · derivative · entry 1 Hehenberger Karin M. · CIK 0001548029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,255 Underlying: Common Stock · 28,255 shares Expires 2033-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 15, 2023. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:26 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 18,573 | $0.00 Strike: $13.46 | $0.00 |
DisclosureSEC source: 0001209191-22-037883 · doc4.xml · derivative · entry 1 Hehenberger Karin M. · CIK 0001548029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,573 Underlying: Common Stock · 18,573 shares Expires 2032-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 15, 2022. Read SEC document |
| August 27, 2021 Filed Sep 1, 2021 00:32 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock option (right to buy) · Derivative | 17,549 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034657 · doc4.xml · derivative · entry 1 Hehenberger Karin M. · CIK 0001548029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,549 Underlying: Common Stock · 17,549 shares Expires 2031-08-27 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month). The grant date is August 27, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.